The Cancer Drug Development Forum (CDDF) will hold a live webinar on “Perspectives on the new EU Health Technology Assessment (HTA) Regulation 2021/2282“ on Thursday 28 September 2023 at 16:00 (CEST) / 10:00 (EDT).
Health Technology Assessment on new medicines that acquired a marketing authorization in the EU, is organized at the level of the EU member states. Unfortunately, in practice, there is unequal access for cancer patients to novel anti-cancer agents.
The EU Regulation 2021/2282 on Health Technology Assessment aims to contribute to improving the availability for EU patients of innovative technologies, such as medicines and certain medical devices. It aims to ensure an efficient use of resources and the strengthen the quality of HTA across the Union. It entered into force in January 2022, and applies as of January 2025.
The Regulation provides a transparent and inclusive framework by establishing a Coordination Group of HTA national and regional authorities, a stakeholder network, and by establishing rules on the involvement in joint clinical assessments and joint scientific consultations of patients, clinical experts and other relevant experts.
This way, it aims to reduce duplication of efforts for national HTA authorities and industry, facilitate business predictability and to ensure long-term sustainability of the EU HTA cooperation.
In this CDDF webinar practical aspects of the establishment on the new regulation will be discussed from the perspective of the assessor by Marcus Guardian (Chief Operating Officer at EUnetHTA), as well as from the patient perspective by Julie Spony (Policy officer at European Patients’ Forum).
Agenda: (CET time zone)
16:00 – 16:05 Introduction – Axel Glasmacher (CDDF, DE)
16:05 – 16:20 Presentation – Marcus Guardian (EUnetHTA, NL)
16:20 – 16:35 Presentation – Julie Spony (European Patients’ Forum, FR)
16:35 – 17:00 Discussion – moderated by Axel Glasmacher (CDDF, DE)